Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hernatogenous metastasis, and prognosis

被引:71
作者
Sato, T
Yamaguchi, A
Goi, T
Hirono, Y
Takeuchi, K
Katayama, K
Matsukawa, S
机构
[1] Univ Fukui, Dept Surg 1, Fukui 9101193, Japan
[2] Univ Fukui, Cent Res Labs, Fukui, Japan
关键词
heparanase; tumor invasion; hematogenous metastasis; angiogenesis; colorectal cancer;
D O I
10.1002/jso.20097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Heparanase is considered to play an important role in tumor invasion and hematogenous metastasis. The aim of this study was to determine the expression of heparanase in colorectal cancer to evaluate its prognostic value. Methods: We analyzed heparanase mRNA derived from 130 colorectal cancer patients by reverse transcription polymerase chain reaction (PCR), compared its expression with clinicopathologic factors, and performed statistical analysis. To investigate the relationship between heparanase expression and tumor angiogenesis, 81 primary colorectal tumors were immunostained by use of a monoclonal anti-CD34 antibody. Results: Thirty three of 130 cancer tissues overexpressed heparanase. There were significant correlations between heparanase expression and serosal invasion, venous invasion, and liver metastasis. Multivariate analyzes revealed that heparanase mRNA overexpression was a significant independent risk factor for hematogenous metastasis in colorectal cancer. Among 104 patients who underwent curative resection, heparanase expression correlated with a high recurrence. The 5-year survival rate was 84.6% for patients with heparanase negative tumors, and 47.7% for those with heparanase overexpression; these differences between two groups of patients were significant. In multivariate analysis using the Cox regression model, heparanese expression emerged as an independent prognostic indicator. Moreover, the tumor angiogenesis of heparanase-positive tumors determined with a monoclonal anti-CD34 antibody was significantly higher than that of heparanase-negative tumors. Conclusions: These results indicated that Heparanase expression may be an important role in invasion and hematogenous metastasis, and may be a biologic marker of prognostic significance in colorectal cancer patients. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:174 / 181
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 1997, AJCC CANC STAGING MA
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   Heparanase: Breaking down barriers in tumors [J].
Eccles, SA .
NATURE MEDICINE, 1999, 5 (07) :735-736
[4]  
El-Assal ON, 2001, CLIN CANCER RES, V7, P1299
[5]   Heparanase as mediator of angiogenesis: mode of action [J].
Elkin, M ;
Ilan, N ;
Ishai-Michaeli, R ;
Friedmann, Y ;
Papo, O ;
Pecker, I ;
Vlodavsky, I .
FASEB JOURNAL, 2001, 15 (07) :1661-+
[6]   Heparin structure and interactions with basic fibroblast growth factor [J].
Faham, S ;
Hileman, RE ;
Fromm, JR ;
Linhardt, RJ ;
Rees, DC .
SCIENCE, 1996, 271 (5252) :1116-1120
[7]   Human platelet heparanase: purification, characterization and catalytic activity [J].
Freeman, C ;
Parish, CR .
BIOCHEMICAL JOURNAL, 1998, 330 :1341-1350
[8]   Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma -: Evidence for its role in colonic tumorigenesis [J].
Friedmann, Y ;
Vlodavsky, I ;
Aingorn, H ;
Aviv, A ;
Peretz, T ;
Pecker, I ;
Pappo, O .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (04) :1167-1175
[9]   Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis [J].
Goldshmidt, O ;
Zcharia, E ;
Abramovitch, R ;
Metzger, S ;
Aingorn, H ;
Friedmann, Y ;
Schirrmacher, V ;
Mitrani, E ;
Vlodavsky, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :10031-10036
[10]   Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts [J].
Goshen, Ran ;
Hochberg, Abraham A. ;
Korner, Gil ;
Levy, Ehud ;
Ishai-Michaeli, Rivka ;
Elkin, Michael ;
de Groot, Nathan ;
Vlodaysky, Israel .
MOLECULAR HUMAN REPRODUCTION, 1996, 2 (09) :679-684